Table 3.
Characteristics of Genetically-matched and Distinct Potential Recipients
| Factor | All New Cases (N = 640) | New Cases With Previous 0–2 SNV Donor (N = 227 [35%]) | New Cases With Previous 3–10 SNV Donor (N = 127 [20%]) | New Cases With All Prior Samples >10 SNVs (N = 286 [45%]) | P Value 0–2 vs 3–10 vs >10 SNVs | P Value 0–2 vs >2 SNVs |
|---|---|---|---|---|---|---|
| Predictors | ||||||
| Female | 376 (59%) | 121 (53%) | 73 (57%) | 182 (64%) | P = .06 | P = .04 |
| Age, years | 76 (61–84) | 81 (70–87) | 71 (58–82) | 71 (51–82) | P < .001 | P < .001 |
| Study start to first sample, days | 255 (126–404) | 250 (157–398) | 326 (161–396) | 234 (82–422) | P = .04 | P = .30 |
| Type of CDI | ||||||
| CA | 121 (19%) | 26 (11%) | 28 (22%) | 67 (23%) | P = .001 (see Supplementary Figure S5) | P < .001 |
| I | 46 (7%) | 11 (5%) | 10 (8%) | 25 (9%) | ||
| CO-HCFA | 126 (20%) | 42 (19%) | 29 (23%) | 55 (19%) | ||
| HO-HCFA | 347 (54%) | 148 (65%) | 60 (47%) | 139 (49%) | ||
| Inpatient on day of diagnosis | 511 (80%) | 184 (81%) | 102 (80%) | 225 (79%) | P = .79 | P = .57 |
| Inpatient days in the 12 wk pre-diagnosis | 16 (4–40) | 27 (10–48) | 13 (3–28) | 13 (2–34) | P < .001 | P < .001 |
| Source isolation on the day of symptom onseta | 177/246 (72%) | 78/111 (70%) | 36/50 (72%) | 63/85 (74%) | P = .84 | P = .60 |
| Ribotype (if >25 cases) | ||||||
| 027 | 105 (16%) | 99 (44%) | 3 (2%) | 3 (1%) | P < .001 | P < .001 |
| 015 | 62 (10%) | 12 (5%) | 23 (18%) | 27 (9%) | P < .001 | P = .005 |
| 078 | 57 (9%) | 26 (11%) | 28 (22%) | 3 (1%) | P < .001 | P = .09 |
| 002 | 55 (9%) | 15 (7%) | 13 (10%) | 27 (9%) | P = .40 | P = .18 |
| 014 | 49 (8%) | 18 (8%) | 2 (2%) | 29 (10%) | P = .004 | P = .85 |
| 020 | 38 (6%) | 14 (6%) | 11 (9%) | 13 (5%) | P = .26 | P = .86 |
| 001/072 | 29 (5%) | 13 (6%) | 4 (3%) | 12 (4%) | P = .56 | P = .32 |
| Other | 245 (38%) | 30 (13%) | 43 (34%) | 172 (60%) | P < .001 | P < .001 |
| Outcomes | ||||||
| Clostridium difficile severity score (n = 516) | ||||||
| 0 | 119 (23%) | 20 (11%) | 28 (26%) | 71 (31%) | P < .001 | P < .001 |
| 1 | 268 (52%) | 111 (61%) | 51 (48%) | 106 (47%) | ||
| 2 | 112 (22%) | 43 (23%) | 24 (22%) | 45 (20%) | ||
| 3 | 17 (3%) | 9 (5%) | 4 (4%) | 4 (2%) | ||
| Inpatient days in the 12 wk post-diagnosis | 16 (4–38) | 20 (5–42) | 12 (4–30) | 15 (4–34) | P = .12 | P = .05 |
| >1 positive sample | 158 (25%) | 73 (32%) | 30 (24%) | 55 (19%) | P = .003 | P = .001 |
| Recurrent CDI (≥14 d) | 136 (21%) | 65 (29%) | 24 (19%) | 47 (16%) | P = .001 | P = .003 |
| 30-d mortality | 120 (19%) | 62 (27%) | 24 (19%) | 34 (12%) | P < .001 | P < .001 |
Numbers show N (%) or median (inter-quartile range), and univariable Kruskal-Wallis (continuous variable) or chi-squared (categorical) tests. Fisher’s exact tests were used where any cell percentage was <5% or any frequency was <5. For ribotypes each comparison is that specific ribotype vs all others pooled.
Abbreviations: CA, community associated: CI, confidence interval; CDI, Clostridium difficile infection; CO-HCFA, community-onset healthcare facility–associated; HO-HCFA, hospital-onset healthcare facility–associated; I, indeterminate; OR, odds ratio; SNV, single nucleotide variants.
aApplicable only to hospital-onset cases: collected from January 2011 where data was available in clinical documentation.